Anitoa Launches Molecular Test (PCR) for Monkeypox

Anitoa | June 30, 2022

Anitoa Systems, market leader in fast, portable molecular testing, today announced the availability of a CE-marked turn-key PCR solution for testing Monkeypox. This portable solution includes one of a family small foot-print real time PCR instruments called the Maverick qPCR, with an extraction-free multiplex PCR reagent that tests OPXV/MPXV gene-targets in the skin lesion sample from patients suspected of infection with Monkeypox. Anitoa's Monkeypox test is designed to be carried out on-site, near patient, thus avoiding the need to transport patient samples to central labs for testing.

The World Health Organization reported that over 2,100 people in 42 countries have been diagnosed with monkeypox as of June 15, nearly all during the past two months. As of June 17, the CDC reports 24 confirmed monkeypox cases in California, US. Although The CDC reports that the threat to the general U.S. population is considered low, it is important for healthcare providers worldwide to have a preparedness plan.

Already having a presence in Africa, Anitoa Systems has started deloying its near-patient Monkeypox test in selected clinics in Africa. Anitoa is prepared to deliver its Monkeypox test solution world-wide when the need arises.

Anitoa's Maverick line of multiplex real time PCR devices are lab-accurate, fast, portable and calibration-free. They can operate on battery power (including car battery) and takes up very little bench space. Maverick qPCR instruments are built on Anitoa's proprietary CMOS biosensor technology. They have been used widely for on-site testing of food, environment samples and agriculture products due to its rugged all solid-state design, small form factor, and lower operation cost.

Anitoa's Monkeypox detection solution is part of an on-going program at Anitoa to develop tests to help combat a series of neglected tropical diseases in low resource settings. These tests currently include IVDR tests for Dengue, Yellow Fever, and Malaria

We are closely monitoring the situation of Monkeypox infections around the world and tailoring our test solutions to the needs of the people affected." 

Zhimin ding, CEO of Anitoa Systems, LLC

About Anitoa
Anitoa Systems, a medical device technology start-up established in 2013 with headquarter in Sunnyvale, California, develops highly integrated and portable bio-sensor devices for molecular detection, based on its unique CMOS image sensor-based fluorescence and chemiluminescence molecular imaging. By replacing the traditional bulky and costly photon-multiplier tube (PMT) and CCD-based optical sub-systems, Anitoa's ultra-low-light CMOS sensor technology enables a new generation of compact and inexpensive molecular testing platforms targeting infectious, oncology and cardio-vascular markers. Anitoa manufactures its qPCR instruments and test kits in Hangzhou, China and Fremont, California.


According to the Wall Street Journal, deep learning systems have a fatal flaw: there is no way to tell how a decision was made. CytoSavvy is a pathology informatics software company using artificial intelligence to attack the big data problem for drug discovery and personalized medicine with a novel shape detection methodology packaged as a browser-based solution.

Other News

Salipro Biotech Obtains Granted Patents in the United States and China for Direct Extraction of Membrane Proteins and Library Generation

Salipro Biotech | September 08, 2022

Salipro Biotech AB, a Swedish biotech company with a leading technology platform for the stabilization of membrane proteins for drug development, announced today that its patent entitled "Saposin lipoprotein particles and libraries from crude membranes" has been issued by both the U.S. Patent and Trademark Office and by the China National Intellectual Property Administration. The patents cover the company's novel method of direct extraction of membrane proteins from cells or crude membranes to enable drug development for challenging drug targets, as well as the generation of Salipro libraries representing the membrane proteome, the particles themselves and their use in drug discovery and membrane protein research, amongst others. The Salipro® technology enables the development of novel therapeutics against drug targets that previously could not be investigated. The award of these patents further strengthens Salipro Biotech's global intellectual property portfolio, with various patents already granted i.a. in the U.S., EU, China and Japan. "We are excited to announce the granting of these patents in the U.S. and in China. This news represents an important corporate achievement that fosters our position to accelerate drug discovery programs with pharma companies on challenging drug targets. Jens Frauenfeld, CEO Maria Knudsen, Business Development Director, comments: "DirectMX® is already being implemented in our partnered drug discovery programs for a range of drug targets, including GPCRs, SLCs and Ion Channels. The addition of these patents to our IP portfolio further solidifies Salipro Biotech's position as a holder of a key drug discovery platform and will enable us to increase the value of our pharma collaborations as well as continue to build our internal pipeline." About Salipro Biotech AB Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies.

Read More



CBC Group | November 21, 2022

RVAC Medicines Pte. Ltd. a messenger RNA technology platform company incubated by CBC Group, a healthcare-dedicated asset management firm headquartered in Singapore, and the Agency for Science, Technology and Research (A*STAR) today announced the signing of a master research collaboration agreement to jointly study and develop solutions to build mRNA manufacturing and analytics capabilities in Singapore. With this collaboration, RVAC and A*STAR will set up a joint laboratory based at A*STAR's Bioprocessing Technology Institute (BTI) to develop a preclinical manufacturing platform, which will facilitate the generation of novel raw materials and potentially clinical-grade assets for the development of mRNA vaccines and therapeutics targeting infectious diseases and other conditions with unmet needs. Leveraging BTI's deep expertise in processing technologies and analytical sciences for biotherapeutics and the strong translational research in biomedical technologies across multiple research institutes in A*STAR, this collaboration seeks to enable local ecosystem innovators and global manufacturers to access the manufacturing platform to aid in preclinical asset development. The collaboration utilizes RVAC's extensive capabilities in mRNA, vaccine, and drug delivery technologies, as well as knowledge and expertise in biopharmaceutical manufacturing, research and development clinical development, and commercialization. RVAC develops mRNA-based vaccines targeting infectious diseases such as COVID-19, for which it initiated a first-in-human vaccine clinical trial in September 2022. Additional RVAC pipeline assets in development include vaccines targeting respiratory syncytial virus and Clostridioides difficile infections. Since its founding in June 2021, RVAC has recruited a team of more than 80 top-tier scientists and experienced industry veterans, and has established R&D centres in Boston, MA, USA and Shanghai, PRC. "Our collaboration with A*STAR brings together innovative research and development experience from some of the world's leading mRNA researchers. We are committed to providing the staff, equipment, and technological expertise, with support from our R&D teams around the world, to this endeavour. Combined with A*STAR's knowledge and experience, this partnership has the potential to continue the advancement of mRNA as a new class of medicines." Dr Sean Fu, Chief Executive Officer of RVAC Professor Ng Huck Hui, Assistant Chief Executive, Biomedical Research Council, A*STAR, said, "Public-private partnerships are key enablers in translating science into impact. A*STAR's multidisciplinary R&D capabilities in infectious diseases, artificial intelligence, analytics and protein engineering, coupled with RVAC's expertise, will advance the development of mRNA vaccines and therapeutics and contribute to better health outcomes for Singapore and beyond." Fu Wei, Chief Executive Officer, CBC Group added, "The collaboration between RVAC and A*STAR is a significant step in supporting the growth of innovative R&D that will ultimately drive the development of advanced vaccines and therapeutics to benefit more patients. This is aligned with CBC's mission of delivering quality and accessible medical innovation across Asia and beyond. The collaboration will also enhance the technological capability of our ecosystem, which fits well with Singapore's commitment to mission-oriented and curiosity-driven R&D." About RVAC Medicines RVAC Medicines is an mRNA platform company headquartered in Singapore with R&D centers in Boston and Shanghai. Leveraging its mRNA technology and strategic partnerships, the company is building a pipeline of novel mRNA vaccines and therapeutics to address unmet medical needs, particularly in emerging markets. The company is led by an experienced management team, supported by a world-renowned scientific advisory board. About CBC Group Headquartered in Singapore, CBC Group is Asia's largest healthcare-dedicated asset management firm, focusing on platform-building, buyout, credit/royalty, and real estate across the healthcare space, including pharmaceutical and biotech, medical technology and healthcare services. CBC is committed to creating lasting value by integrating global innovations and talents. Partnering with the world's top entrepreneurs and scientists, its unique "investor-operator" approach has empowered leading healthcare companies to widen access to affordable medical care, catalyse innovations and improve efficiency in fulfilling unmet medical needs worldwide. Founded in 2014, CBC has built a world class team of investment, industry and portfolio management professionals, headquartered in Singapore with locations in Shanghai, Beijing, Hong Kong, New York, London, and Seoul. About the Agency for Science, Technology and Research The Agency for Science, Technology and Research is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis.

Read More


Lysando AG and Amicogen Inc. Sign General Development Agreement

Lysando AG and Amicogen Inc. | October 19, 2022

Lysando AG market leader in the field of antimicrobial proteins has signed a general development agreement with Amicogen Inc., a publicly traded biotechnology company and CDMO headquartered in South Korea. In August last year, Lysando and Amicogen entered into a strategic partnership backed up by a mutual participation model. This collaboration has since been further intensified, now culminating in aforementioned general development agreement. "Amicogen is our first choice for process development and scale-up of any new Artilysin®. This important step in our partnership with Amicogen will help our customers to significantly shorten the time-to-market of Artilysin®-powered products." Count Markus Matuschka de Greiffenclau, Chairman of the Board of Directors of Lysando AG Amicogen is an established and professional partner enabling Lysando to develop its own projects to market-readiness at maximum speed, thus further accelerating Lysando’s entry into the pharmaceutical industry. Ongoing projects targeting indications such as urinary tract infections or neurodermatitis are progressing well. About Amicogen Inc. Amicogen Inc is a CDMO and biotechnology company based in Jinju, South Korea. Amicogen is a leader in the development and production of specialty enzymes and proteins for the biopharmaceutical, food, cosmetics and other industries. One of Amicogen's core competencies is the use of new technologies such as directed gene evolution. The heart of the business is a novel approach that uses biocatalysts to replace chemical with enzymatic processes. These biocatalysts provide an environmentally friendly manufacturing process for downstream industries reducing emissions, simplifying production processes and increasing productivity. About Lysando AG Lysando AG is the market leader for antimicrobial proteins, so-called Artilysin®s. They can effectively eliminate problem-causing bacteria without associated high risk of resistance formation and microbial disbalances. Artilysin®s constitute an innovative, proprietary and environmentally friendly technology with a wide range of applications: in human and veterinary medicine, but for example also in cosmetics. Lysando AG's research facility is Lysando Innovations Lab GmbH located in Regensburg's BioPark. BioPark Regensburg fosters companies in biotechnology, medical technology, diagnostics & analytics as well as the local healthcare management.

Read More


Illumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery

Illumina, Inc. | October 12, 2022

Illumina Inc. a global leader in DNA sequencing and array-based technologies, announced a strategic research collaboration with AstraZeneca, a global, science-led biopharmaceutical company, to accelerate drug target discovery by combining their strengths in artificial intelligence (AI) based genome interpretation and genomic analysis techniques along with industry expertise. The collaboration will evaluate whether a combined framework of these technologies can increase the yield and confidence of target discovery to find promising drugs based on human omics insights. "Illumina and AstraZeneca are uniquely positioned to improve the efficiency of pharma pipelines by leveraging industry-leading abilities to identify genetic variants that contribute to human disease. By identifying genes that show evidence of human disease causality, the combined framework has the potential to prioritize drug candidates with increased likelihood of approval." Joydeep Goswami, chief strategy and corporate development officer, interim chief financial officer at Illumina The collaboration leverages Illumina's next generation of AI-based interpretation tools, PrimateAI and SpliceAI, in combination with AstraZeneca's analysis framework for rare variant genomic discoveries—alongside the latter's own AI tools, including JARVIS and in silico predictors like missense tolerance ratio. As part of the research collaboration a framework combining the two companies' AI-based tools will be adopted by AstraZeneca's Centre for Genomics Research to analyze large-scale multi-omics data sets in its digital biobank. The complementary AI tools work to more confidently pinpoint genetic variants that contribute to human diseases, a critical step in the process of developing effective and safe therapies. Slavé Petrovski, head of AstraZeneca's Centre for Genomics Research, Discovery Sciences, R&D, said: "Continuous innovation in the AI tools and frameworks that are applied to the growing human genomics, transcriptomics, and proteomics medical research resources will enable us to answer some of the toughest questions and contribute to our aims of uncovering novel drug targets with a higher probability of success while also characterizing patient subgroups that are most likely to benefit from the treatments we discover." "The next generation of drug discovery lies at the intersection of human genetics and AI, making this a potentially pivotal research collaboration that combines Illumina's industry-leading ability to interpret genomes at scale with AstraZeneca's extensive capabilities in large-scale human genetics research," said Alex Aravanis, chief technology officer of Illumina. The research collaboration focuses on the ability of a combined framework to deliver differential performance across a broad range of human diseases. Upon its successful outcome, the two companies will assess opportunities for a long-term partnership. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Read More


According to the Wall Street Journal, deep learning systems have a fatal flaw: there is no way to tell how a decision was made. CytoSavvy is a pathology informatics software company using artificial intelligence to attack the big data problem for drug discovery and personalized medicine with a novel shape detection methodology packaged as a browser-based solution.